N-[2-(phenylmethoxy)ethyl]aniline | 71126-63-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(phenylmethoxy)ethyl]aniline
• 英文别名: (2-benzyloxy-ethyl)-phenyl-amine；(2-benzyloxyethyl)phenylamine；N-(2-(benzyloxy)ethyl)aniline；β-Benzyloxy-N-phenylethylamin；N-Phenyl-2-benzyloxyethylamine；N-(2-phenylmethoxyethyl)aniline
• CAS: 71126-63-1
• 化学式: C₁₅H₁₇NO
• 分子量: 227.306
• InChiKey: YAOUBSNJEKGSGP-UHFFFAOYSA-N

物化性质

• 沸点：
  373.3±25.0 °C(Predicted)
• 密度：
  1.087±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[2-(phenylmethoxy)ethyl]aniline 在 草酰氯 、 水 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 [9-(2-benzyloxy-ethyl)-2,3,4,9-tetrahydro-1H-carbazol-4-yl]-piperidin-1-yl-methanone
  参考文献：
  名称：

  [18F]GE-180: A novel fluorine-18 labelled PET tracer for imaging Translocator protein 18kDa (TSPO)

  摘要：

  A series of tricyclic compounds have been synthesised and evaluated in vitro for affinity against Translocator protein 18 kDa (TSPO) and for preferred imaging properties. The most promising of the compounds were radiolabelled and evaluated in vivo to determine biodistribution and specificity for high expressing TSPO regions. Metabolite profiling in brain and plasma was also investigated. Evaluation in an autoradiography model of neuroinflammation was also carried out for the best compound, 12a ([F-18]GE-180). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.084
• 作为产物：
  描述：

  N-phenyl-2-(phenylmethoxy)acetamide 在 [Ru(κ3-(1,1,1-tris-(diphenylphosphinomethyl)ethane))(CO)(H)2] 、 三氟化硼乙醚 、 氢气 、 对甲苯磺酸 作用下， 以 四氢呋喃 为溶剂， 120.0 ℃ 、5.07 MPa 条件下， 反应 16.0h， 以91%的产率得到N-[2-(phenylmethoxy)ethyl]aniline
  参考文献：
  名称：

  硼路易斯酸促进钌催化的酰胺加氢：仲胺的有效方法

  摘要：

  已通过使用催化剂[Ru（H）2（CO）（Triphos）]（Triphos = 1,1,1,1-tri（diphenylphosphinomethyl）ethane）和催化硼路易斯酸（例如B（ ç 6 ˚F 5）3或BF 3 ⋅的Et 2 O作为添加剂。该反应提供了以高收率和高选择性从酰胺制备仲胺的有效方法。

  DOI：

  10.1002/cctc.201600635

文献信息

• Ru‐Catalyzed Deoxygenative Transfer Hydrogenation of Amides to Amines with Formic Acid/Triethylamine
  作者：Yixiao Pan、Zhenli Luo、Xin Xu、Haoqiang Zhao、Jiahong Han、Lijin Xu、Qinghua Fan、Jianliang Xiao

  DOI：10.1002/adsc.201900406

  日期：2019.8.21

  ruthenium(II)‐catalyzed deoxygenative transfer hydrogenation of amides to amines using HCO2H/NEt3 as the reducing agent is reported for the first time. The catalyst system consisting of [Ru(2‐methylallyl)2(COD)], 1,1,1‐tris(diphenylphosphinomethyl) ethane (triphos) and Bis(trifluoromethane sulfonimide) (HNTf2) performed well for deoxygenative reduction of various secondary and tertiary amides into the corresponding

  首次报道了使用HCO 2 H / NEt 3作为还原剂的钌（II）催化的酰胺脱氧转移胺成胺。催化剂体系由[Ru（2-甲基烯丙基）2（COD）]，1,1,1-三（二苯基膦甲基）乙烷（triphos）和双（三氟甲烷磺酰亚胺）（HNTf 2）在将各种仲酰胺和叔酰胺脱氧还原成相应的胺方面表现出色，选择性极好，并且对包括还原敏感基团在内的官能团表现出很高的耐受性。氢源和酸助催化剂的选择对于催化至关重要。机理研究表明，通过借入氢对原位生成的醇和胺进行还原胺化是主要途径。
• Deoxygenative Hydrogenation of Amides Catalyzed by a Well-Defined Iridium Pincer Complex
  作者：Ming-Lei Yuan、Jian-Hua Xie、Shou-Fei Zhu、Qi-Lin Zhou

  DOI：10.1021/acscatal.6b01019

  日期：2016.6.3

  The iridium-catalyzed highly chemoselective hydrogenation of amides to amines has been developed. Using a well-defined iridium catalyst bearing a P(O)C(O)P pincer ligand combined with B(C6F5)3, the C–O cleavage products are formed under mild reaction conditions. The reaction provides a new method for the preparation of amines from amides in good yield with high selectivity.

  已经开发了铱催化的酰胺高度化学选择性氢化成胺的方法。使用带有P（O）C（O）P钳形配体与B（C 6 F 5）3结合的明确定义的铱催化剂，在温和的反应条件下可形成C–O裂解产物。该反应提供了一种以高收率和高选择性从酰胺制备胺的新方法。
• Boron Lewis Acid Promoted Ruthenium-Catalyzed Hydrogenation of Amides: An Efficient Approach to Secondary Amines
  作者：Ming-Lei Yuan、Jian-Hua Xie、Qi-Lin Zhou

  DOI：10.1002/cctc.201600635

  日期：2016.10.6

  The hydrogenation of amides to amines has been developed by using the catalyst [Ru(H)2(CO)(Triphos)] (Triphos=1,1,1‐tri(diphenylphosphinomethyl)ethane) and catalytic boron Lewis acids such as B(C6F5)3 or BF3⋅Et2O as additives. The reaction provides an efficient method for the preparation of secondary amines from amides in good yields with high selectivity.

  已通过使用催化剂[Ru（H）2（CO）（Triphos）]（Triphos = 1,1,1,1-tri（diphenylphosphinomethyl）ethane）和催化硼路易斯酸（例如B（ ç 6 ˚F 5）3或BF 3 ⋅的Et 2 O作为添加剂。该反应提供了以高收率和高选择性从酰胺制备仲胺的有效方法。
• Indole derivatives
  申请人：GE Healthcare Limited

  公开号：US09220795B2

  公开（公告）日：2015-12-29

  An indole-based in vivo imaging agent is provided by the present invention that binds with high affinity to PBR, has good uptake into the brain following administration, and which has good selective binding to PBR. The invention also includes a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. Also provided is a cassette for automated synthesis of the in vivo imaging agent. Further aspects of the invention include a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, and methods for the use of said in vivo imaging agent.

  本发明提供了一种吲哚基体内成像剂，该成像剂与PBR具有高亲和力，给药后能够良好地进入大脑，并且对PBR具有优良的选择性结合。本发明还包括用于合成本发明的体内成像剂的先驱化合物，以及一种使用所述先驱化合物的合成所述体内成像剂的方法，以及用于执行所述方法的试剂盒。还提供了一种用于自动合成体内成像剂的盒式磁带。发明的进一步方面包括一种放射性药物组合物，该组合物包含本发明的体内成像剂，以及使用所述体内成像剂的方法。
• In vivo imaging method for cancer
  申请人：Jones Paul Alexander

  公开号：US09314541B2

  公开（公告）日：2016-04-19

  The present invention provides a method useful in the diagnosis and monitoring of cancer wherein there is an abnormal expression of PBR. The method of the invention is particularly useful in evaluating the severity of the cancer, e.g. PBR expression correlates with cell proliferation rates, metastatic potential, tumor aggressiveness, malignancy progression. The method of the invention can therefore be applied in the determination of likely disease progression and in making an associated prognosis. Furthermore, the method of the invention can find use in determining the likely success of certain therapeutic approaches, or in the evaluation of the efficacy of certain proposed new treatments.

  本发明提供了一种在癌症的诊断和监测中有用的方法，其中PBR的表达异常。本发明的方法特别适用于评估癌症的严重程度，例如PBR表达与细胞增殖率、转移潜力、肿瘤侵袭性、恶性进展相关。因此，本发明的方法可以应用于确定可能的疾病进展，并作出相关的预后。此外，本发明的方法可以用于确定某些治疗方法的成功可能性，或评估某些提议的新治疗方法的有效性。